At the Kiawah Eye 2015 meeting, Reid Turner, MD, presented results from a study at the Storm Eye Institute that investigated long-term outcomes of angle-supported ACIOLs in pediatric patients.
Uncategorized
Uncategorized
Ocata Therapeutics to Ring the NASDAQ Stock Market Opening Bell on June 24, 2015
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Company management will ring The NASDAQ Opening Bell at 9:30 am EDT on June 24, 2015 at The NASDAQ Marketsite in New York City. “We are pleased to have been invited to open the NASDAQ and as a leader in regenerative ophthalmology are delighted to be part of this leading stock exchange,” said Paul K. Wotton Ph.D., Presi
Uncategorized
Sikka Software Raises $10.5 Million Series C Round to Increase its Rapidly Expanding Share of Cloud-based Retail Healthcare
MILPITAS, Calif.–(BUSINESS WIRE)–Sikka Software, the leading retail healthcare cloud platform, raised its Series C funding of $10.5 million led by OrbiMed with participation from its Series B investor, Sierra Ventures and Series A investor, ATA Ventures. This new capital will further accelerate Sikka to scale sales and marketing and continue its rapid growth across key practice areas. “OrbiMed is impressed with the Sikka team and what they have accomplished to date and we are excited about th
Injectable drug ocriplasmin improves vision in patients with symptomatic vitreomacular adhesion
In two ancillary studies of two multi-center international clinical trials led by the University of Southern California Eye Institute, the injectable drug ocriplasmin appears to improve vision among patients suffering from symptomatic vitreomacular adh…
Eye’s motion detection sensors identified
Driving a car at 40 mph, you see a child dart into the street. You hit the brakes. Disaster averted.But how did your eyes detect that movement? It’s a question that has confounded scientists.
A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye
Status: Recruiting,
Condition Summary: Dry Eye Disease